Loading...
•
Dec 31, 2022
10X Genomics Q4 2022 Earnings Report
Reported a revenue increase of 9% compared to the same period last year.
Key Takeaways
10x Genomics reported Q4 2022 revenue of $156.2 million, a 9% increase year-over-year. The company's operating loss was $23.1 million, and net loss was $17.2 million. They also provided full year 2023 revenue guidance of $580 million to $600 million.
Q4 2022 revenue increased by 9% year-over-year, reaching $156.2 million.
Full year 2022 revenue increased by 5% year-over-year, reaching $516.4 million.
Cumulative instruments sold surpassed 4,600 by the end of 2022.
Shipping of the Xenium platform for in situ analysis commenced.
Forward Guidance
10x Genomics expects full year 2023 revenue to be in the range of $580 million to $600 million, representing 12% to 16% growth over full year 2022 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...